Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

The Distinct Roles of CXCR3 Variants and Their Ligands in the Tumor Microenvironment.

Reynders N, Abboud D, Baragli A, Noman MZ, Rogister B, Niclou SP, Heveker N, Janji B, Hanson J, Szpakowska M, Chevigné A.

Cells. 2019 Jun 18;8(6). pii: E613. doi: 10.3390/cells8060613. Review.

2.

Irradiation to Improve the Response to Immunotherapeutic Agents in Glioblastomas.

Nesseler JP, Schaue D, McBride WH, Lee MH, Kaprealian T, Niclou SP, Nickers P.

Adv Radiat Oncol. 2018 Nov 20;4(2):268-282. doi: 10.1016/j.adro.2018.11.005. eCollection 2019 Apr-Jun. Review.

3.

Stem cell-associated heterogeneity in Glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment.

Dirkse A, Golebiewska A, Buder T, Nazarov PV, Muller A, Poovathingal S, Brons NHC, Leite S, Sauvageot N, Sarkisjan D, Seyfrid M, Fritah S, Stieber D, Michelucci A, Hertel F, Herold-Mende C, Azuaje F, Skupin A, Bjerkvig R, Deutsch A, Voss-Böhme A, Niclou SP.

Nat Commun. 2019 Apr 16;10(1):1787. doi: 10.1038/s41467-019-09853-z.

4.

Hub genes in a pan-cancer co-expression network show potential for predicting drug responses.

Azuaje F, Kaoma T, Jeanty C, Nazarov PV, Muller A, Kim SY, Dittmar G, Golebiewska A, Niclou SP.

Version 2. F1000Res. 2018 Dec 7 [revised 2019 Jan 1];7:1906. doi: 10.12688/f1000research.17149.2. eCollection 2018.

5.

A DNA Repair and Cell-Cycle Gene Expression Signature in Primary and Recurrent Glioblastoma: Prognostic Value and Clinical Implications.

Gobin M, Nazarov PV, Warta R, Timmer M, Reifenberger G, Felsberg J, Vallar L, Chalmers AJ, Herold-Mende CC, Goldbrunner R, Niclou SP, Van Dyck E.

Cancer Res. 2019 Mar 15;79(6):1226-1238. doi: 10.1158/0008-5472.CAN-18-2076. Epub 2019 Jan 23.

PMID:
30674534
6.

Transcriptional and epigenetic mechanisms underlying astrocyte identity.

Pavlou MAS, Grandbarbe L, Buckley NJ, Niclou SP, Michelucci A.

Prog Neurobiol. 2019 Mar;174:36-52. doi: 10.1016/j.pneurobio.2018.12.007. Epub 2018 Dec 29. Review.

7.

Distribution and prognostic impact of microglia/macrophage subpopulations in gliomas.

Zeiner PS, Preusse C, Golebiewska A, Zinke J, Iriondo A, Muller A, Kaoma T, Filipski K, Müller-Eschner M, Bernatz S, Blank AE, Baumgarten P, Ilina E, Grote A, Hansmann ML, Verhoff MA, Franz K, Feuerhake F, Steinbach JP, Wischhusen J, Stenzel W, Niclou SP, Harter PN, Mittelbronn M.

Brain Pathol. 2019 Jul;29(4):513-529. doi: 10.1111/bpa.12690. Epub 2019 Jan 15.

PMID:
30506802
8.

Single-cell transcriptomics reveals distinct inflammation-induced microglia signatures.

Sousa C, Golebiewska A, Poovathingal SK, Kaoma T, Pires-Afonso Y, Martina S, Coowar D, Azuaje F, Skupin A, Balling R, Biber K, Niclou SP, Michelucci A.

EMBO Rep. 2018 Nov;19(11). pii: e46171. doi: 10.15252/embr.201846171. Epub 2018 Sep 11.

9.

RNAi/CRISPR Screens: from a Pool to a Valid Hit.

Schuster A, Erasimus H, Fritah S, Nazarov PV, van Dyck E, Niclou SP, Golebiewska A.

Trends Biotechnol. 2019 Jan;37(1):38-55. doi: 10.1016/j.tibtech.2018.08.002. Epub 2018 Aug 31. Review.

PMID:
30177380
10.

Revival of the VEGF ligand family?

Niclou SP.

Neuro Oncol. 2018 Oct 9;20(11):1421-1422. doi: 10.1093/neuonc/noy127. No abstract available.

PMID:
30137575
11.

EGFL7 enhances surface expression of integrin α5β1 to promote angiogenesis in malignant brain tumors.

Dudvarski Stanković N, Bicker F, Keller S, Jones DT, Harter PN, Kienzle A, Gillmann C, Arnold P, Golebiewska A, Keunen O, Giese A, von Deimling A, Bäuerle T, Niclou SP, Mittelbronn M, Ye W, Pfister SM, Schmidt MHH.

EMBO Mol Med. 2018 Sep;10(9). pii: e8420. doi: 10.15252/emmm.201708420.

12.

Increased formate overflow is a hallmark of oxidative cancer.

Meiser J, Schuster A, Pietzke M, Vande Voorde J, Athineos D, Oizel K, Burgos-Barragan G, Wit N, Dhayade S, Morton JP, Dornier E, Sumpton D, Mackay GM, Blyth K, Patel KJ, Niclou SP, Vazquez A.

Nat Commun. 2018 Apr 10;9(1):1368. doi: 10.1038/s41467-018-03777-w.

13.

Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia.

Wierz M, Pierson S, Guyonnet L, Viry E, Lequeux A, Oudin A, Niclou SP, Ollert M, Berchem G, Janji B, Guérin C, Paggetti J, Moussay E.

Blood. 2018 Apr 5;131(14):1617-1621. doi: 10.1182/blood-2017-06-792267. Epub 2018 Feb 13. No abstract available.

14.

Altered metabolic landscape in IDH-mutant gliomas affects phospholipid, energy, and oxidative stress pathways.

Fack F, Tardito S, Hochart G, Oudin A, Zheng L, Fritah S, Golebiewska A, Nazarov PV, Bernard A, Hau AC, Keunen O, Leenders W, Lund-Johansen M, Stauber J, Gottlieb E, Bjerkvig R, Niclou SP.

EMBO Mol Med. 2017 Dec;9(12):1681-1695. doi: 10.15252/emmm.201707729.

15.

Regulation of hypoxia-induced autophagy in glioblastoma involves ATG9A.

Abdul Rahim SA, Dirkse A, Oudin A, Schuster A, Bohler J, Barthelemy V, Muller A, Vallar L, Janji B, Golebiewska A, Niclou SP.

Br J Cancer. 2017 Sep 5;117(6):813-825. doi: 10.1038/bjc.2017.263. Epub 2017 Aug 10.

16.

Carboxypeptidase E transmits its anti-migratory function in glioma cells via transcriptional regulation of cell architecture and motility regulating factors.

Armento A, Ilina EI, Kaoma T, Muller A, Vallar L, Niclou SP, Krüger MA, Mittelbronn M, Naumann U.

Int J Oncol. 2017 Aug;51(2):702-714. doi: 10.3892/ijo.2017.4051. Epub 2017 Jun 21.

PMID:
28656234
17.

Lack of functional normalisation of tumour vessels following anti-angiogenic therapy in glioblastoma.

Obad N, Espedal H, Jirik R, Sakariassen PO, Brekke Rygh C, Lund-Johansen M, Taxt T, Niclou SP, Bjerkvig R, Keunen O.

J Cereb Blood Flow Metab. 2018 Oct;38(10):1741-1753. doi: 10.1177/0271678X17714656. Epub 2017 Jun 19.

18.

Harnessing LRIG1-mediated inhibition of receptor tyrosine kinases for cancer therapy.

Neirinckx V, Hedman H, Niclou SP.

Biochim Biophys Acta Rev Cancer. 2017 Aug;1868(1):109-116. doi: 10.1016/j.bbcan.2017.02.007. Epub 2017 Mar 1. Review.

PMID:
28259645
19.

Combined VEGFR and CTLA-4 blockade increases the antigen-presenting function of intratumoral DCs and reduces the suppressive capacity of intratumoral MDSCs.

Du Four S, Maenhout SK, Niclou SP, Thielemans K, Neyns B, Aerts JL.

Am J Cancer Res. 2016 Nov 1;6(11):2514-2531. eCollection 2016.

20.

The angiogenic switch leads to a metabolic shift in human glioblastoma.

Talasila KM, Røsland GV, Hagland HR, Eskilsson E, Flønes IH, Fritah S, Azuaje F, Atai N, Harter PN, Mittelbronn M, Andersen M, Joseph JV, Hossain JA, Vallar L, Noorden CJ, Niclou SP, Thorsen F, Tronstad KJ, Tzoulis C, Bjerkvig R, Miletic H.

Neuro Oncol. 2017 Mar 1;19(3):383-393. doi: 10.1093/neuonc/now175.

21.

EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation.

Eskilsson E, Rosland GV, Talasila KM, Knappskog S, Keunen O, Sottoriva A, Foerster S, Solecki G, Taxt T, Jirik R, Fritah S, Harter PN, Välk K, Al Hossain J, Joseph JV, Jahedi R, Saed HS, Piccirillo SG, Spiteri I, Leiss L, Euskirchen P, Graziani G, Daubon T, Lund-Johansen M, Enger PØ, Winkler F, Ritter CA, Niclou SP, Watts C, Bjerkvig R, Miletic H.

Neuro Oncol. 2016 Dec;18(12):1644-1655. Epub 2016 Jun 10. Erratum in: Neuro Oncol. 2016 Dec;18(12 ):e2.

22.

Analysis of the dynamic co-expression network of heart regeneration in the zebrafish.

Rodius S, Androsova G, Götz L, Liechti R, Crespo I, Merz S, Nazarov PV, de Klein N, Jeanty C, González-Rosa JM, Muller A, Bernardin F, Niclou SP, Vallar L, Mercader N, Ibberson M, Xenarios I, Azuaje F.

Sci Rep. 2016 May 31;6:26822. doi: 10.1038/srep26822.

23.

Molecular crosstalk between tumour and brain parenchyma instructs histopathological features in glioblastoma.

Bougnaud S, Golebiewska A, Oudin A, Keunen O, Harter PN, Mäder L, Azuaje F, Fritah S, Stieber D, Kaoma T, Vallar L, Brons NH, Daubon T, Miletic H, Sundstrøm T, Herold-Mende C, Mittelbronn M, Bjerkvig R, Niclou SP.

Oncotarget. 2016 May 31;7(22):31955-71. doi: 10.18632/oncotarget.7454.

24.

Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma.

Tardito S, Oudin A, Ahmed SU, Fack F, Keunen O, Zheng L, Miletic H, Sakariassen PØ, Weinstock A, Wagner A, Lindsay SL, Hock AK, Barnett SC, Ruppin E, Mørkve SH, Lund-Johansen M, Chalmers AJ, Bjerkvig R, Niclou SP, Gottlieb E.

Nat Cell Biol. 2015 Dec;17(12):1556-68. doi: 10.1038/ncb3272. Epub 2015 Nov 23.

25.

Targeted Proteomics to Assess the Response to Anti-Angiogenic Treatment in Human Glioblastoma (GBM).

Demeure K, Fack F, Duriez E, Tiemann K, Bernard A, Golebiewska A, Bougnaud S, Bjerkvig R, Domon B, Niclou SP.

Mol Cell Proteomics. 2016 Feb;15(2):481-92. doi: 10.1074/mcp.M115.052423. Epub 2015 Aug 4.

26.

Intercellular transfer of transferrin receptor by a contact-, Rab8-dependent mechanism involving tunneling nanotubes.

Burtey A, Wagner M, Hodneland E, Skaftnesmo KO, Schoelermann J, Mondragon IR, Espedal H, Golebiewska A, Niclou SP, Bjerkvig R, Kögel T, Gerdes HH.

FASEB J. 2015 Nov;29(11):4695-712. doi: 10.1096/fj.14-268615. Epub 2015 Jul 28.

PMID:
26220176
27.

Axitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model.

Du Four S, Maenhout SK, De Pierre K, Renmans D, Niclou SP, Thielemans K, Neyns B, Aerts JL.

Oncoimmunology. 2015 Jan 22;4(4):e998107. eCollection 2015 Apr.

28.

Gauging heterogeneity in primary versus recurrent glioblastoma.

Niclou SP.

Neuro Oncol. 2015 Jul;17(7):907-9. doi: 10.1093/neuonc/nov078. Epub 2015 May 12. No abstract available.

29.

Comprehensive analysis of glycolytic enzymes as therapeutic targets in the treatment of glioblastoma.

Sanzey M, Abdul Rahim SA, Oudin A, Dirkse A, Kaoma T, Vallar L, Herold-Mende C, Bjerkvig R, Golebiewska A, Niclou SP.

PLoS One. 2015 May 1;10(5):e0123544. doi: 10.1371/journal.pone.0123544. eCollection 2015.

30.

Therapeutic control and resistance of the EGFR-driven signaling network in glioblastoma.

Azuaje F, Tiemann K, Niclou SP.

Cell Commun Signal. 2015 Mar 31;13:23. doi: 10.1186/s12964-015-0098-6. Review.

31.

Whole genomes redefine the mutational landscape of pancreatic cancer.

Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K, Quinn MC, Robertson AJ, Fadlullah MZ, Bruxner TJ, Christ AN, Harliwong I, Idrisoglu S, Manning S, Nourse C, Nourbakhsh E, Wani S, Wilson PJ, Markham E, Cloonan N, Anderson MJ, Fink JL, Holmes O, Kazakoff SH, Leonard C, Newell F, Poudel B, Song S, Taylor D, Waddell N, Wood S, Xu Q, Wu J, Pinese M, Cowley MJ, Lee HC, Jones MD, Nagrial AM, Humphris J, Chantrill LA, Chin V, Steinmann AM, Mawson A, Humphrey ES, Colvin EK, Chou A, Scarlett CJ, Pinho AV, Giry-Laterriere M, Rooman I, Samra JS, Kench JG, Pettitt JA, Merrett ND, Toon C, Epari K, Nguyen NQ, Barbour A, Zeps N, Jamieson NB, Graham JS, Niclou SP, Bjerkvig R, Grützmann R, Aust D, Hruban RH, Maitra A, Iacobuzio-Donahue CA, Wolfgang CL, Morgan RA, Lawlor RT, Corbo V, Bassi C, Falconi M, Zamboni G, Tortora G, Tempero MA; Australian Pancreatic Cancer Genome Initiative, Gill AJ, Eshleman JR, Pilarsky C, Scarpa A, Musgrove EA, Pearson JV, Biankin AV, Grimmond SM.

Nature. 2015 Feb 26;518(7540):495-501. doi: 10.1038/nature14169.

32.

A novel multilayer immunoisolating encapsulation system overcoming protrusion of cells.

Bhujbal SV, de Haan B, Niclou SP, de Vos P.

Sci Rep. 2014 Oct 31;4:6856. doi: 10.1038/srep06856.

33.

Databases for lncRNAs: a comparative evaluation of emerging tools.

Fritah S, Niclou SP, Azuaje F.

RNA. 2014 Nov;20(11):1655-65. doi: 10.1261/rna.044040.113. Review.

34.

Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas.

Fack F, Espedal H, Keunen O, Golebiewska A, Obad N, Harter PN, Mittelbronn M, Bähr O, Weyerbrock A, Stuhr L, Miletic H, Sakariassen PØ, Stieber D, Rygh CB, Lund-Johansen M, Zheng L, Gottlieb E, Niclou SP, Bjerkvig R.

Acta Neuropathol. 2015 Jan;129(1):115-31. doi: 10.1007/s00401-014-1352-5. Epub 2014 Oct 17.

35.

PeptideManager: a peptide selection tool for targeted proteomic studies involving mixed samples from different species.

Demeure K, Duriez E, Domon B, Niclou SP.

Front Genet. 2014 Sep 2;5:305. doi: 10.3389/fgene.2014.00305. eCollection 2014.

36.

Multimodal imaging of gliomas in the context of evolving cellular and molecular therapies.

Keunen O, Taxt T, Grüner R, Lund-Johansen M, Tonn JC, Pavlin T, Bjerkvig R, Niclou SP, Thorsen F.

Adv Drug Deliv Rev. 2014 Sep 30;76:98-115. doi: 10.1016/j.addr.2014.07.010. Epub 2014 Jul 28. Review.

37.

Colorectal cancer derived organotypic spheroids maintain essential tissue characteristics but adapt their metabolism in culture.

Rajcevic U, Knol JC, Piersma S, Bougnaud S, Fack F, Sundlisaeter E, Søndenaa K, Myklebust R, Pham TV, Niclou SP, Jiménez CR.

Proteome Sci. 2014 Jul 11;12:39. doi: 10.1186/1477-5956-12-39. eCollection 2014.

38.

Factors influencing the mechanical stability of alginate beads applicable for immunoisolation of mammalian cells.

Bhujbal SV, Paredes-Juarez GA, Niclou SP, de Vos P.

J Mech Behav Biomed Mater. 2014 Sep;37:196-208. doi: 10.1016/j.jmbbm.2014.05.020. Epub 2014 Jun 2.

PMID:
24951926
39.

Combined effect of tissue stabilization and protein extraction methods on phosphoprotein analysis.

Kofanova OA, Fack F, Niclou SP, Betsou F.

Biopreserv Biobank. 2013 Jun;11(3):161-5. doi: 10.1089/bio.2013.0008. Epub 2013 May 29.

PMID:
24850093
40.

U-251 revisited: genetic drift and phenotypic consequences of long-term cultures of glioblastoma cells.

Torsvik A, Stieber D, Enger PØ, Golebiewska A, Molven A, Svendsen A, Westermark B, Niclou SP, Olsen TK, Chekenya Enger M, Bjerkvig R.

Cancer Med. 2014 Aug;3(4):812-24. doi: 10.1002/cam4.219. Epub 2014 May 8.

41.

Glutamate as chemotactic fuel for diffuse glioma cells: are they glutamate suckers?

van Lith SA, Navis AC, Verrijp K, Niclou SP, Bjerkvig R, Wesseling P, Tops B, Molenaar R, van Noorden CJ, Leenders WP.

Biochim Biophys Acta. 2014 Aug;1846(1):66-74. doi: 10.1016/j.bbcan.2014.04.004. Epub 2014 Apr 18. Review.

PMID:
24747768
42.

Bevacizumab treatment for human glioblastoma. Can it induce cognitive impairment?

Fathpour P, Obad N, Espedal H, Stieber D, Keunen O, Sakariassen PØ, Niclou SP, Bjerkvig R.

Neuro Oncol. 2014 May;16(5):754-6. doi: 10.1093/neuonc/nou013.

43.

Drug and cell encapsulation: alternative delivery options for the treatment of malignant brain tumors.

Bhujbal SV, de Vos P, Niclou SP.

Adv Drug Deliv Rev. 2014 Apr;67-68:142-53. doi: 10.1016/j.addr.2014.01.010. Epub 2014 Jan 31. Review.

PMID:
24491927
44.

Tumor versus stromal cells in culture--survival of the fittest?

Talasila KM, Brekka N, Mangseth K, Stieber D, Evensen L, Rosland GV, Torsvik A, Wagner M, Niclou SP, Mahesparan R, Vintermyr OK, Bjerkvig R, Nigro JM, Miletic H.

PLoS One. 2013 Dec 2;8(12):e81183. doi: 10.1371/journal.pone.0081183. eCollection 2013.

45.

Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and α-KG.

Navis AC, Niclou SP, Fack F, Stieber D, van Lith S, Verrijp K, Wright A, Stauber J, Tops B, Otte-Holler I, Wevers RA, van Rooij A, Pusch S, von Deimling A, Tigchelaar W, van Noorden CJ, Wesseling P, Leenders WP.

Acta Neuropathol Commun. 2013 May 29;1:18. doi: 10.1186/2051-5960-1-18.

46.

Glioblastomas are composed of genetically divergent clones with distinct tumourigenic potential and variable stem cell-associated phenotypes.

Stieber D, Golebiewska A, Evers L, Lenkiewicz E, Brons NH, Nicot N, Oudin A, Bougnaud S, Hertel F, Bjerkvig R, Vallar L, Barrett MT, Niclou SP.

Acta Neuropathol. 2014 Feb;127(2):203-19. doi: 10.1007/s00401-013-1196-4. Epub 2013 Oct 24.

47.

Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia.

Baginska J, Viry E, Berchem G, Poli A, Noman MZ, van Moer K, Medves S, Zimmer J, Oudin A, Niclou SP, Bleackley RC, Goping IS, Chouaib S, Janji B.

Proc Natl Acad Sci U S A. 2013 Oct 22;110(43):17450-5. doi: 10.1073/pnas.1304790110. Epub 2013 Oct 7.

48.

Gene set based integrated data analysis reveals phenotypic differences in a brain cancer model.

Petersen K, Rajcevic U, Abdul Rahim SA, Jonassen I, Kalland KH, Jimenez CR, Bjerkvig R, Niclou SP.

PLoS One. 2013 Jul 9;8(7):e68288. doi: 10.1371/journal.pone.0068288. Print 2013.

49.

The soluble form of the tumor suppressor Lrig1 potently inhibits in vivo glioma growth irrespective of EGF receptor status.

Johansson M, Oudin A, Tiemann K, Bernard A, Golebiewska A, Keunen O, Fack F, Stieber D, Wang B, Hedman H, Niclou SP.

Neuro Oncol. 2013 Sep;15(9):1200-11. doi: 10.1093/neuonc/not054. Epub 2013 May 30.

50.

A novel, diffusely infiltrative xenograft model of human anaplastic oligodendroglioma with mutations in FUBP1, CIC, and IDH1.

Klink B, Miletic H, Stieber D, Huszthy PC, Campos Valenzuela JA, Balss J, Wang J, Schubert M, Sakariassen PØ, Sundstrøm T, Torsvik A, Aarhus M, Mahesparan R, von Deimling A, Kaderali L, Niclou SP, Schröck E, Bjerkvig R, Nigro JM.

PLoS One. 2013;8(3):e59773. doi: 10.1371/journal.pone.0059773. Epub 2013 Mar 19. Erratum in: PLoS One. 2013;8(8). doi:10.1371/annotation/72a01ce5-b0ad-4cbd-ac77-0a81347a3940. Valenzuela, Jaime Alberto Campos [corrected to Campos Valenzuela, Jaime Alberto].

Supplemental Content

Loading ...
Support Center